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ABSTRACT
Propofol is an intravenous anesthetic commonly used due to its favorable pharmacoki-
netic and pharmacodynamic profile. There are discrepancies in the literature about the
most appropriate sample for determining propofol concentrations. Although plasma
has been used for determining propofol concentrations, whole blood has been the
preferred sample. There is also a lack of consistency in the literature on the effect
of storage time and temperature on propofol concentrations and this may lead to
errors in the design of pharmacokinetic/pharmacodynamics studies. The purpose of
this study was to determine the difference in propofol concentrations in whole blood
versus plasma and to evaluate the influence of storage time (56 days) and temperature
(4 ◦C, −20 ◦C, −80 ◦C) on the stability of propofol concentrations in blood and
plasma samples. Results from the study indicate that whole blood and plasma samples
containing propofol stored at −80 ◦C have concentrations as high as or higher than
those stored at 4 ◦C or−20 ◦C for 56 days; thus,−80 ◦C is an appropriate temperature
for propofol sample storage. Plasma propofol concentrations were consistently higher
than whole blood for all three storage temperatures. Consequently, plasma is the most
appropriate sample for propofol analysis due to its consistent determinations.
Subjects Veterinary Medicine, Pharmacology
Keywords Propofol, Stability, Blood, Plasma, Temperature
INTRODUCTION
Propofol is a short-acting intravenous anesthetic, which is associated with smooth and
rapid inductions and recovery and is commonly used in dogs and other veterinary patients
(Robertson, Johnston & Beemsterboer, 1992; Zoran, Riedesel & Dyer, 1993; Mandsager et al.,
1995; Lee et al., 2012; Zonca et al., 2012; Miryabe-Nishiwake et al., 2013; Gomulka et al.,
2015; Cattai et al., 2016). Propofol is weakly acidic, and drugs of this type are generally
considered to bind to albumin in plasma. It is also a lipophilic drug, and despite being
highly (98%) bound to serum/plasma proteins (Servin et al., 1988; Campos et al., 2016),
it is approximately 50% bound to erythrocytes (Mazoit & Samili, 1999). Data from
pharmacokinetic/pharmacodynamics studies based on the relationship between blood
propofol concentrations and its effects have been used to design propofol dosage
regimens for anesthesia (Cuadrado et al., 1998); however, differences in measured propofol
concentrations due to the effects of storage time and temperature on plasma and whole
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blood samples may influence the dosage regimen design. Blood has been the medium of
choice for determining propofol concentrations (Adam et al., 1981;Plummer, 1987;Chan &
So, 1990; Zonca et al., 2012; Cattai et al., 2016). However, plasma (or serum) has been used
for pharmacokinetic and pharmacodynamics studies, information comparing propofol
concentrations in those fluids with whole blood is scarce: in some studies, a plasma/blood
ratio of one or less has been described; therefore, propofol may be equally distributed
between plasma and blood (Servin et al., 1988; Coetzee et al., 1995; Cuadrado et al., 1998).
Whether plasma concentrations reflect the effects of propofol in humans and animals
better than whole blood concentrations also remains to be established. Consequently, there
is discussion in the literature as to whether propofol concentrations should be determined
in whole blood or serum/plasma samples.
The method used to store samples may influence the concentration of drugs. It has
been suggested that blood samples used for propofol determination should not be frozen
(Plummer, 1987), and that propofol concentrations in samples stored at 4 ◦C are stable for
up to one week (Adam et al., 1981; Zonca et al., 2012), two weeks (Cuadrado et al., 1998)
or 12 weeks (Plummer, 1987). Bienert et al. (2005) suggested that blood should be stored
at 4 ◦C but not at −20 ◦C because of significant propofol loss, however, they recommend
that samples should be analyzed as soon as possible. They also suggest that plasma samples
are stable at 4 ◦C for 60 days, and plasma provides a better matrix for propofol analysis.
The pharmacokinetics of propofol have been widely investigated, usually by determina-
tion of propofol in whole blood by the use of high performance liquid chromatography.
The authors’ laboratory started analyzing propofol samples in 2009 and, at that time,
whole blood analysis for propofol seemed to be the most appropriate method because of its
interaction with erythrocytes. However, due to recent discussions in the literature it was felt
that a re-evaluation of the sample matrix for propofol analysis was warranted. Additionally,
samples are stored−80 ◦C in the laboratory and presently there are no data in the literature
about sample stability at this temperature. Thus, the purpose of this study was to determine
the effect of storage duration and temperature on stability of propofol concentrations in
blood and plasma and determine if blood or plasma is an appropriate sample matrix. To
achieve the objectives of this study, the following three specific aims were pursued: (1)
compared the stability of propofol concentrations between blood and plasma samples. It
was hypothesized that plasma is an acceptable sample for propofol studies. (2) Determined
the stability of propofol concentrations at 4 ◦C, −20 ◦C, and −80 ◦C storage temperatures
in blood and plasma. The working hypothesis was that −80 ◦C is an acceptable storage
temperature for propofol studies. (3) Determined the stability of propofol concentrations
at various storage periods (Day 1, 7, 14, 21, 28, 35, 42, 49 and 56) in blood and plasma. It was
hypothesized that the stability of propofol would decrease with increased storage duration.
MATERIALS AND METHODS
Equipment
Propofol was separated on a Waters XBridge C18 (4.6 × 250 mm, 5 µm) column with
an XBridge C18 guard column. The mobile phase was a mixture of (A) water adjusted to
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Figure 1 Plasma concentrations spiked with (A) 1,500 and (B) 3,500 ng/mL of propofol stored at 4 ◦C,
20 ◦C, and−80 ◦C for 56 days. The number of replicates per day is one.
pH 4.0 with glacial acetic acid and (B) acetonitrile (31:69). The flow rate was 1.5 mL/min
and the column temperature ambient (24 ◦C). The fluorescence detector was set at an
excitation of 276 nm and an emission of 310 nm with the gain at 10×.
Reagents and solutions
Propofol was purchased from US Pharmacopeia (Rockford, MD, USA), and 2,4-ditert-
butylphenol (purity 99%) was purchased from Sigma-Aldrich (Saint Louis, MO, USA). All
other reagent grade chemicals were purchased from Fisher Scientific (Pittsburg, PA, USA).
Water was obtained from a Barnstead (Dubuque, IA, USA) Nanopure Infinity ultrapure
water system.
Propofol and 2,4-ditert-butylphenol (internal standard) were dissolved in methanol
to produce stock solutions of 100 µg/mL. Dilutions of the propofol stock solution were
prepared to produce 1 and 10µg/mLworking stock solutions. Standardswere aliquoted into
2 mL vials to prevent evaporation and cross contamination. All solutions were protected
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Figure 2 Blood concentrations spiked with (A) 17 and (B) 3,500 ng/mL of propofol stored at 4 ◦C,
20 ◦C, and−80 ◦C for 56 days. The number of replicates per day is one.
from light in bottles wrapped in aluminum foil and stored at−20 ◦C. Standards were stable
for four months at this temperature. Standard curves were prepared by fortifying untreated
plasma or blood with propofol to produce a linear concentration range of 5–7,000 ng/mL.
The final concentrations used were 5, 10, 25, 50, 100, 250, 500, 1,000, 1,500, 2,000, 2,500,
5,000, and 7,000 ng/mL.
Sample collection
Fifteen adult, male dogs from the UTCVM research colony were determined to be healthy
based on results of physical examination; chemistry panel and history were used. Venous
blood collected from the jugular vein of each dog was pooled to minimize the impact of
individual differences in blood composition (i.e., hematocrit, total protein concentrations)
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Table 1 Propofol plasma concentrations measured for 56 days at 4 ◦C,−20 ◦C, and−80 ◦C.
Temp Concentration at different days of storage
Starting conc. Day 1* Day 7 Day 14 Day 21 Day 28 Day 35 Day 42 Day 49 Day 56
4 ◦C
17 17 20 19 13 16 12 16 11 13
150 155 155 157 153 169 126 123 153 147
350 347 336 310 357 357 313 325 323 246
1,500 1,514 1,506 1,419 1,508 1,517 1,221 1,320 1,300 1,342
3,500 3,226 3,396 3,225 3,349 3,439 2,847 2,912 2,940 3,229
5,500 5,379 4,414 5,033 4,687 5,156 4,541 4,349 4,284 4,235
−20 ◦C
17 17 12 13 13 10 18 11 17 14
150 155 147 157 154 142 128 137 145 142
350 347 351 288 354 356 326 324 261 282
1,500 1,514 1,509 1,459 1,509 1,415 1,271 1,320 1,385 1,388
3,500 3,226 3,158 3,136 3,283 3,191 2,693 2,533 2,703 2,912
5,500 5,379 4,471 3,717 4,779 5,456 4,036 4,176 4,407 3,886
−80 ◦C
17 17 15 16 16 15 13 13 13 13
150 155 169 160 154 153 140 131 140 162
350 347 347 346 353 340 313 314 337 357
1,500 1,514 1,514 1,503 1,508 1,518 1,277 1,348 1,338 1,631
3,500 3,226 3,325 3,271 3,223 3,534 2,827 2,667 2,407 2,431
5,500 5,379 5,156 5,425 5,331 5,526 4,642 4,242 3,980 4,540
Notes.
Results reported in ng/mL; n= 1.
*Day 1 samples were not frozen but analyzed immediately after spiking.
among dogs. The volume of blood collected from each dog did not exceed 1% of body
weight in kilograms. The study was approved by the Institutional Animal Care and Use
Committee at the University of Tennessee (Protocol number 2241-0214).
Enough pooled blood was centrifuged to provide plasma for the plasma portion of the
study. All blood and plasma samples were immediately spiked with propofol calibration
standards (17, 150, 350, 1,500, 3,500, and 5,500 ng/mL) and placed in vials labeled day 1,
7, 14, 21, 28, 35, 42, 49 and 56 for analysis on those dates. Samples were then placed in
their respective storage locations (4 ◦C, −20 ◦C, −80 ◦C). Day 1 samples were analyzed
immediately after spiking. Only one sample was analyzed for each propofol concentration
evaluated (i.e., no replicates).
Extraction procedure
Canine plasma and blood samples were analyzed using a reverse phase high-performance
liquid chromatography (HPLC) method (Yarbrough, Harvey & Cox, 2012). The system
consisted of a 2695 separations module, a 2475 fluorescence detector and a computer
equipped with Empower software. Propofol was extracted from plasma or blood samples
by a liquid extraction method. Briefly, previously frozen samples were thawed and vortexed
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Table 2 Propofol blood concentrations measured for 56 days at 4 ◦C,−20 ◦C, and−80 ◦C.
Temp Concentration at different days of storage
Starting conc. Day 1* Day 7 Day 14 Day 21 Day 28 Day 35 Day 42 Day 49 Day 56
4 ◦C
17 18 16 16 21 16 19 17 22 13
150 149 145 145 141 140 145 141 133 126
350 355 345 344 351 351 227 196 220 179
1,500 1,490 1,417 1,314 1,296 1,238 792 913 1,030 825
3,500 3,189 2,409 2,457 2,340 2,426 1,918 1,947 1,817 1,878
5,500 4,558 3,974 4,074 3,878 4,246 3,972 3,431 3,512 2,713
−20 ◦C
17 18 17 23 26 10 5 5 9 ND
150 149 122 163 163 73 53 35 60 ND
350 355 190 217 254 280 159 115 115 92
1,500 1,490 1,160 1,233 1,217 1,418 1,122 909 1,003 777
3,500 3,189 2,257 3,156 3,139 2,659 1,788 1,262 1,301 1,007
5,500 4,558 4,309 4,184 4,729 4,126 3,455 2,994 3,026 2,404
−80 ◦C
17 18 16 21 25 19 20 19 21 19
150 149 154 133 1355 142 151 150 158 155
350 355 341 358 345 349 304 357 312 300
1,500 1,490 1,201 1,375 1,297 1,488 1,196 1,198 1,293 1,289
3,500 3,189 2,286 3,122 3,112 2,966 2,430 2,422 2,388 2,225
5,500 4,558 4,092 4,766 4,570 4,528 3,986 3,822 3,870 3,655
Notes.
ND, no propofol detected in sample; results reported at ng/mL; n= 1.
*Day 1 samples were not frozen but analyzed immediately after spiking.
and 400 µL were transferred to a clean test tube followed by 10 µL of internal standard
(100 µg/mL 2,4-ditert-butylphenol). One milliliter of acetonitrile-methanol (75:25) was
added and the tubes vortex mixed, covered and placed in the refrigerator for 10 min. The
tubes were vortex mixed for 10 s and centrifuged for 15 min at 1,000× g. The supernatant
was removed to a clean tube. The procedure was repeated with an additional 0.5 mL of
acetonitrile-methanol, and that supernatant combined. The tubes were centrifuged for 5
min and supernatant was placed in chromatographic vials and 100 µL analyzed.
Statistical analysis
Actual values and comparative changes in values of the different measured propofol
concentrations in blood and plasma samples at varying storage temperatures were used
to summarize the effect of storage length on stability of propofol concentration. Percent
changes in values at the different days ofmeasurementwere also used to evaluate the effect of
storage on propofol concentration. Graphical representations of some of the above-assessed
effects are presented. Validation parameters for plasma were also calculated.
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Table 3 Propofol plasma concentrations measured for 56 days at 4 ◦C,−20 ◦C, and−80 ◦C.
Temp Percentage change in concentration from starting concentration
Starting conc.
(ng/mL)
Day 1 Day 7 Day 14 Day 21 Day 28 Day 35 Day 42 Day 49 Day 56
4 ◦C
17 0 17.65 11.76 −23.53 −5.88 −29.64 −5.88 −35.29 −23.53
150 3.33 3.33 4.67 2 12.67 −16 −18 2 −2
350 −0.86 −4 −11.43 2 2 −10.62 −7.03 −7.85 −29.71
1,500 0.93 0.40 −5.40 0.53 1.13 −18.62 −12.02 −13.30 −10.53
3,500 −7.83 −2.98 −7.87 −4.31 −1.74 −18.64 −16.80 −16.01 −7.75
5,500 −2.2 −19.75 −8.50 −14.78 −6.25 −17.43 −20.93 −22.12 −23.01
−20 ◦C
17 0 −29.41 −23.53 −23.53 −41.18 5.88 −35.29 0 −17.65
150 3.33 −2 4.67 2.67 −5.33 −14.67 −8.67 −3.33 −5.33
350 −0.86 0.39 −17.67 1.14 1.17 −6.80 −7.55 −25.43 −19.43
1,500 0.93 0.60 −2.71 0.60 1.20 −15.26 −11.97 −7.66 −7.47
3,500 −7.83 −9.76 −10.40 −6.2 −8.82 −23.06 −27.62 −22.76 −16.80
5,500 −2.20 −18.72 −32.43 −13.11 −0.80 −26.62 −24.07 −19.87 −29.34
−80 ◦C
17 0 −11.76 −5.88 −5.88 −11.76 −23.53 −23.53 −23.53 −23.53
150 3.33 12.67 6.67 2.67 2 −6.67 −12.67 −6.67 8
350 −0.86 −0.86 −1.14 0.86 −2.86 −10.47 −10.17 −3.80 2
1,500 0.93 0.93 0.20 0.53 1.20 −14.86 −10.16 −10.79 8.73
3,500 −7.83 −5.00 −6.53 −7.91 0.97 −19.22 −23.80 −31.22 −30.54
5,500 −2.20 −6.25 −1.37 −3.08 0.47 −15.60 −22.52 −27.63 −17.45
RESULTS
Samples were analyzed on days 1, 7, 14, 21, 28, 35, 42, 49, and 56. Concentrations were
determined with the exception of two blood samples (17 and 150 ng/mL) on day 56 stored
at −20 ◦C that did not result in any detectable propofol. In both sample media (blood
and plasma), samples stored at −20 ◦C resulted in the lowest propofol measurements of
all 3 storage temperatures evaluated. Samples stored at −80 ◦C had the highest propofol
measurements for both media.
Actual values of the different measured propofol concentrations in plasma and in blood
at various storage temperatures are reported in Tables 1 and 2 while the percentage of
variation of the propofol concentrations compared to the starting concentration are listed
in Tables 3 and 4. This information was used to summarize the effect of storage length
on the stability of propofol concentration. Due to the large number of graphs generated
by this study, graphical representations of the above assessed effect are only presented for
two plasma (1,500 and 5,500 ng/mL) and blood (17 and 3,500 ng/mL) concentrations
(Figs. 1A, 1B, 2A and 2B).
The same method of analysis that was previously used for propofol in whole blood
(Yarbrough, Harvey & Cox, 2012) was used to analyze propofol plasma samples. The
method of analysis in plasma produced a linear curve over the same concentration range as
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Table 4 Propofol blood concentrations measured for 56 days at 4 ◦C,−20 ◦C, and−80 ◦C.
Temp Percentage change in concentration from starting concentration
Starting
conc. (ng/mL)
Day 1 Day 7 Day 14 Day 21 Day 28 Day 35 Day 42 Day 49 Day 56
4 ◦C
17 5.88 −5.88 −5.88 23.53 −5.88 11.76 0 31.03 −24.84
150 −0.67 −3.04 −3.25 −6 −6.52 3.04 −5.70 −11.62 −16.32
350 1.43 −1.43 −1.64 0.29 0.29 −35.25 −44 −37.26 −48.91
1,500 −0.67 −5.50 −12.38 −13.61 −17.45 −47.23 −39.14 −31.32 −45
3,500 −8.89 −31.17 −29.81 −33.15 −30.69 −45.20 −44.36 −48.10 −46.34
5,500 −17.13 −27.13 −25.92 −29.50 −22.80 −27.78 −37.62 −36.14 −50.67
−20 ◦C
17 5.88 0 35.29 35.29 −42.86 −69.89 −70.59 −46.47 ND
150 −0.67 −18.57 8.67 8.67 −51.45 −64.52 −76.78 −60.23 ND
350 1.34 −45.75 −38.14 −27.43 −19.93 −54.57 −67.14 −67.03 −73.71
1,500 −0.67 −22.68 −17.8 −18.87 −5.48 −25.19 −39.39 −33.14 −48.17
3,500 −8.89 −35.53 −9.82 −10.32 −24.04 −48.91 −63.94 −62.82 −71.24
5,500 −17.12 −21.65 −23.92 −14.02 −24.99 −37.19 −45.57 −44.99 −56.30
−80 ◦C
17 5.88 −5.88 23.53 47.06 11.76 17.65 11.76 23.53 11.76
150 −0.67 2.67 −11.33 −10 −5.33 0.63 0 5.33 3.33
350 1.34 −2.51 2.29 −1.43 −0.29 −13.11 2 −10.92 −14.29
1,500 −0.67 −19.90 −8.33 −13.53 −0.80 −20.27 −20.17 −13.77 −14.04
3,500 −8.89 −34.69 −10.80 −11.09 −15.25 −30.56 −30.81 −31.76 −36.42
5,500 −17.13 −25.59 −13.35 −16.91 −17.67 −27.53 −30.51 −29.64 −33.55
Notes.
ND, no propofol detected in sample.
blood (5–7,000 ng/mL) with and r2 greater than 0.999. The intra and inter-assay variability
ranged from 2.8%–10% and 3.8%–6.0%, respectively which is very similar to what was
observed in the whole blood assay (intra and inter-assay variability ranged from 2.0 to
10% and 0.6 to 11%). The average propofol plasma recovery was 91% while the average
recovery for 2,4-ditert-butylphenol was 90%. These recovery values were the same as those
for whole blood propofol. The lower limit of quantification was 5 ng/mL, which is the same
as the value for whole blood. Calibration curves were constructed each day of analysis for
whole blood and plasma.
DISCUSSION
In order to determine the optimal conditions required for storing propofol samples, blood
and plasma were collected from healthy canines and the samples were pooled in order to
reduce the effects of inter-individual variability. A method of analysis, which was originally
developed, for determination of propofol in blood samples was applied and validated for
analysis of plasma samples. To determine whether blood or plasma was the appropriate
sample matrix and to determine the effect of storage temperature and duration, blood and
plasma samples were spiked with various amounts of propofol that fell within a validated
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linear concentration range, and stored at three different temperatures (4 ◦C, −20 ◦C,
−80 ◦C), and analyzed at various times up to 56 days.
Propofol was detected in blood for all six concentrations for the entire 56 days except
for 17 and 150 ng/mL stored at −20 ◦C on day 56. This could be due to degradation of
propofol by enzymes contained in the blood or strong binding to or even penetration into
solid blood elements. There was a decrease in propofol concentrations after day 21 for all
six concentrations. The impact was greater on samples stored at −20 ◦C, with an overall
average loss of 32% from day 21 to 28. There was some propofol loss for the six different
concentrations at 4 ◦C (9%) and −80 ◦C (7%) but it is not as dramatic as the loss of
propofol in samples stored at −20 ◦C. The overall loss of propofol from day 1 to day 56
ranged from 37%, 73% and 12% for 4 ◦C,−20 ◦C, and−80 ◦C, respectively. The majority
of the samples stored at −80 ◦C had higher concentrations than those stored at 4 ◦C and
−20 ◦C which suggests that −80 ◦C would be an acceptable temperature to store whole
blood propofol samples.
There were few differences in concentrations among the storage temperatures for plasma
samples. Propofol was detected in plasma for all six concentrations for the 56-day duration.
However, after 28 days there was a decrease in propofol concentration for 150, 350, 1,500,
3,500 and 5,500 ng/mL for all three temperatures. The overall average loss was 18%, 15%,
and 14% for 4 ◦C, −20 ◦C, and −80 ◦C, respectively. The overall loss of propofol from
day 1 to day 56 ranged from 15%, 15% and 8% for 4 ◦C,−20 ◦C, and−80 ◦C, respectively.
In general, the concentrations were more consistent in plasma than in blood among the
different storage temperatures. However, blood and plasma propofol samples stored at
−20 ◦C had lower concentrations than those stored at 4 ◦C and −80 ◦C.
There were differences between plasma and blood propofol concentrations stored at the
three different temperatures. There were large differences in concentrations between plasma
and blood at 4 ◦C for 1,500, 3,500 and 5,500 ng/mL and there were also differences in the
350, 1,500, 3,500, and 5,500 ng/mL concentrations stored at −20 ◦C. Similar differences
were also detected at −80 ◦C, with plasma having greater concentrations at 17, 1,500,
3,500, and 5,500 ng/mL. Although not all plasma propofol concentrations were larger than
blood concentrations, many of the individual plasma concentrations were larger than the
corresponding blood concentrations, which suggests that plasma would be suitable for
propofol analysis.
This method of analysis was applied to samples collected from a study (Reed et al., 2015)
conducted previously in this facility in which canines were anesthetized with intravenously
administered propofol (6 mg/kg loading dose with mean continuous rate infusion of 0.45
mg/kg/min for 185 ± 32 min) (Table 5). Whole blood and plasma samples were obtained
and analyzed within two weeks of collection, after storage at −80 ◦C. Plasma samples
averaged 37% higher concentrations than the same whole blood samples. This is slightly
higher than the average difference between the spiked blood and plasma samples from the
current stability study. Because the samples were determined with different calibration
curves, this may have had an impact on the results; however, any differences should be
minor because regression lines and other validation parameters were similar between the
two matrices.
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Table 5 Canine propofol results in blood and plasma samples collected at different time points during
general anesthesia induced with an intravenous administration of 6 mg/kg and continuous rate infu-





Mitchell W 1,355 4,143
Mitchell E 3,795 7,207
Mitchell 60 6,194 6,799
Quincy W 1,395 2,388
Quincy E 1,952 3,209
Quincy 60 5,713 7,275
Houston W 2,497 4,073
Houston E 5,717 9,061
Houston 60 3,840 5,658
Notes.
Mean anesthesia time (±SD) was 185± 32 min. W, samples collected at walking when animals were able to walk upon recov-
ery from anesthesia; E, samples collected at endotracheal extubation time upon recovery from anesthesia; 60, samples collected
at 60 min after anesthetic induction.
Although blood has been recommended as the preferred sample for the analysis of
propofol concentrations by some authors (Adam et al., 1981; Plummer, 1987; Chan &
So, 1990; Zonca et al., 2012; Cattai et al., 2016) the results of the present study indicate
a difference between blood and plasma propofol concentrations, at least under
the experimental conditions applied in the study. Moreover, the plasma propofol
determinations were more consistent than whole blood determinations. Thus, it is
important to stress that from an analytical standpoint plasma is the most appropriate
sample matrix for propofol analysis. Plasma was also determined to be the sample of choice
when compared to blood in a study conducted by Bienert et al. (2005). Plasma was also
found to have more consistent results when compared to blood propofol concentrations in
mammalian species (Grossherr et al., 2007). Dawidowicz, Fornal & Fijalkowska (2000) also
saw a significant decrease in blood propofol concentrations compared to minor changes in
plasma samples during 24 days of storage.
CONCLUSION
In summary, whole blood and plasma samples containing propofol stored at −80 ◦C have
concentrations as high as or higher than those stored at 4 ◦C or −20 ◦C for 56 days; thus,
−80 ◦C is an appropriate temperature for propofol sample storage. While the purpose of
the study was not to determine a specific storage time if you apply the FDA Bioanalytical
Guidelines for method development that states a value should be within 15% deviation
from a standard, then somewhere between 28 and 35 days would be an appropriate storage
time for plasma and roughly 21 days for blood. Plasma propofol concentrations were
consistently higher than whole blood for all 3 storage temperatures and from Reed et al.
(2015) canine study samples. Consequently, plasma is a more suitable sample matrix than
blood for propofol analysis providing consistent determinations. The HPLC method that
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was developed and validated allows for the determination of whole blood and plasma
propofol concentrations and is appropriate for use in pharmacokinetic studies.
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